B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumaband implications for study design

Table 5 Adverse events reported in published studies^a during or afterrituximab-induced B-cell depletion therapy

Infections	Pneumonia^b
	Shingles^b
	Thigh abscess, subcutaneous abscess
	Urinary tract infection
	Septicaemia
	Psuedomonas infection
	Staphyloccal abscess
	Streptococcal viridans infection
	Necrotising fasciitis
	Fatal histoplasmosis
Haematological	Neutropenia^b
Pulmonary	Pneumonia
	Pulmonary haemorrhage
	Pulmonary embolism
	Respiratory failure^c
	Breathlessness
Cardiac	Cardiac failure^c
	Fatal pancarditis^c
	Pericarditis
	Tachycardia
Neurological	Insomnia
	Transient ischaemic attack
Skin	Localised or widespread rash^b
	Pruritis
	Urticaria
Miscellaneous	Infusion reactions^b
	Serum sickness reaction
	Hypogammaglobulinaemia
	Anaphylaxis
	Deep vein thrombosis
	Dyspepsia
	Malaise
	Pyrexia
	Polyarthralgia

^aSee Table 1. ^bFrequently reported adverse event.^cLife-threatening complications.

ISSN: 1478-6362